Sarepta Therapeutics (NASDAQ:SRPT) Shares Pass Above 200 Day Moving Average - Here's Why

Key Points

• Sarepta shares passed above their 200-day moving average
• Analysts are mixed: the consensus rating is Hold with a $32.63 average price target, driven by 9 Buy, 13 Hold and 6 Sell recommendations and recent target revisions in the $13–$25 range.
• Recent results showed a large EPS miss—(‑$3.58) vs. est. (‑$0.87)—even though revenue of $442.9M beat estimates but fell 32.7% YoY; the company remains unprofitable and disclosed insider selling while institutional investors own about 86.7% of shares.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $20.40 and traded as high as $22.49. Sarepta Therapeutics shares last traded at $21.73, with a volume of 2,135,402 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SRPT. HC Wainwright reiterated a "sell" rating on shares of Sarepta Therapeutics in a report on Monday, March 2nd. Royal Bank Of Canada boosted their price target on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a "sector perform" rating in a report on Tuesday, April 7th. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Citigroup upped their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a "sell" rating in a research note on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a "sell" rating in a research note on Thursday, March 26th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Hold" and a consensus price target of $32.63.

Sarepta Therapeutics Stock Performance

The stock has a market capitalization of $2.28 billion, a P/E ratio of -2.57, a P/E/G ratio of 0.31 and a beta of 0.29. The stock has a 50 day moving average of $18.94 and a 200 day moving average of $20.40. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. During the same quarter in the previous year, the company earned $1.90 earnings per share. Sarepta Therapeutics's quarterly revenue was down 32.7% compared to the same quarter last year. Equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the business's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares in the company, valued at approximately $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. CWM LLC boosted its position in Sarepta Therapeutics by 4,033.3% during the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company's stock worth $1,401,000 after acquiring an additional 70,946 shares during the period. Aberdeen Group plc boosted its position in Sarepta Therapeutics by 59.6% during the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company's stock worth $38,208,000 after acquiring an additional 740,360 shares during the period. Boxer Capital Management LLC boosted its position in Sarepta Therapeutics by 900.0% during the 3rd quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company's stock worth $4,818,000 after acquiring an additional 225,000 shares during the period. Mirador Capital Partners LP acquired a new position in Sarepta Therapeutics during the 4th quarter worth $3,012,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Sarepta Therapeutics by 143.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company's stock worth $2,410,000 after acquiring an additional 62,981 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.